Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus CAPOX in advanced gastric cancer
NCT04263870Phase 2Unknown
- Sponsor
- Sichuan University
- Start
- Mar 2020
- Primary completion
- May 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of sintilimab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Sichuan University. Status: unknown.
02
Drugs
sintilimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04263870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04263870.